|
|
|
| Clinical effect of Tiotropium Bromide combined with Formoterol inhalation in the treatment of chronic obstructive pulmonary disease |
| LIU Wen-hua |
| Department of Respiratory Medicine,Guixi People′s Hospital,Jiangxi Province,Guixi 335400,China |
|
|
|
|
Abstract Objective To investigate the clinical effect of Tiotropium Bromide combined with Formoterol inhalation in the treatmentof chronic obstructive pulmonary disease.Methods Sixty patients with chronic obstructive pulmonary disease admitted to our hospital from February 2017 to February 2019 were selected as the research subjects,and they were divided into the control group(30 cases)and the observation group(30 cases)according to the random number table method.Patients in the control group were treated with Tiotropium Bromide alone,and patients in the observation group were given Tiotropium Bromide combined with Formoterol inhalation.The clinical efficacy and incidence of adverse reactions of the two groups of patients were observed,and the lung function(forced expiratory volume in one second[FEV1],forced vital capacity[FVC],FEV1 to FVC ratio[FEV1/FVC]),maximal voluntary ventilation(MVV)],dyspnea scale(MRC)score and 6min walking distance(6MWD)before and after treatmentwere compared between the two groups of patients.Results The total effective rate of treatment in the observation group was higher than that in the control group,and the difference was statistically significant(P＜0.05).The FEV1,FVC,FEV1/FVC,and MVV after treatment in the observation group were higher than those in the control group,and the differences were statistically significant(P＜0.05).The MRC score of patients in the observation group was lower than that in the control group,the 6MWD was farther than that in the control group,and the differences were statistically significant(P＜0.05).No serious adverse reactions occurred during the treatment of the two groups.Conclusion Tiotropium Bromide combined with Formoterol inhalation in the treatment of patients with chronic obstructive pulmonary disease has significant effect,it can increase pulmonary function,improve dyspnea,enhance exercise tolerance,and promote outcome of the disease,which has certain safety.
|
|
|
|
|
|
| [10] |
余霓雯，王玉婷.噻托溴铵联合布地奈德福莫特罗对慢性阻塞性肺疾病的疗效及血清TGF-β、MMP-9、TIMP-1水平的影响[J].东南国防医药，2017，19（2）：183-186.
|
| [11] |
郁震，曹娟，王红梅，等.噻托溴铵联合沙美特罗替卡松对慢阻肺急性加重期患者免疫功能的影响[J].临床肺科杂志，2016，21（5）：795-798.核82例临床观察[J].中医杂志，2018，59（19）：56-58.
|
| [12] |
郑燕冰.吸入激素联合噻托溴铵治疗哮喘-慢阻肺重叠综合征的临床效果[J].中国当代医药，2018，25（18）：42-44.
|
| [13] |
李研，佟飞，米香.布地奈德福莫特罗粉吸入剂联合噻托溴铵粉吸入剂治疗ACOS的疗效及其对患者血清hs-CRP、EOS的影响[J].海南医学，2017，28（18）：2997-3000.
|
| [14] |
方佳，肖翔，李瑞金，等.噻托溴铵联合福莫特罗/布地奈德治疗哮喘-慢性阻塞性肺疾病重叠综合征的疗效分析[J].临床内科杂志，2018，35（3）：203-204.
|
| [15] |
樊有，顾晓燕，蒋德升.噻托溴铵联合N-乙酰半胱氨酸及呼吸训练治疗稳定期中度慢阻肺的临床观察[J].临床肺科杂志，2016，21（3）：498-501.
|
| [16] |
汪雨珠.布地奈德福莫特罗吸入治疗对慢阻肺合并肺癌稳定期患者的疗效及价值分析[J].中国医学创新，2019，16（8）：115-118.
|
| [1] |
张祥乐，何美燕，邓玲，等.布地奈德福莫特罗吸入辅治哮喘伴慢性阻塞性肺疾病对肺功能及炎性因子的影响[J].疑难病杂志，2018，17（1）：5-9.
|
| [2] |
张三红，杜磊，邹珍.噻托溴铵对慢阻肺急性加重期肺部感染患者氧合指数与肺功能的影响及疗效观察[J].贵州医药，2018，42（6）：690-692.
|
| [3] |
胡海涛，曾丽娟，屈磊，等.噻托溴铵联合吸入糖皮质激素对哮喘-慢阻肺重叠综合征患者肺功能、FeNO及免疫功能的影响[J].空军医学杂志，2017，33（2）：113-117.
|
| [4] |
中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南（2013年修订版）[J].中华结核和呼吸杂志，2013，36（4）：255-264.
|
| [5] |
刘颖，薄晓霞，张亚娟.布地奈德福莫特罗、噻托溴铵、家庭无创正压通气对慢性阻塞性肺疾病患者影响的研究[J].临床肺科杂志，2018，24（8）：1380-1384.
|
| [6] |
张华根，曾伟坚，彭贵霞，等.布地奈德福莫特罗粉吸入剂联合孟鲁司特钠在哮喘-慢阻肺重叠综合征患者治疗中的应用研究[J].实用药物与临床，2018，21（7）：811-814.
|
| [7] |
张永庆，苗毅，尚立群，等.布地奈德福莫特罗联合噻托溴铵治疗中重度慢阻肺稳定期疗效观察[J].陕西医学杂志，2016，45（4）：494-495.
|
| [8] |
曾林淼，俞晓莲，张清华，等.噻托溴铵联合布地奈德/福莫特罗与单用噻托溴铵治疗慢性阻塞性肺疾病患者的Meta分析[J].中国呼吸与危重监护杂志，2016，29（2）：119-126.
|
| [9] |
刘雪琴，关晓暄，孙立军.噻托溴铵联合沙美特罗/氟替卡松治疗哮喘——慢阻肺重叠综合征的临床评价[J].临床肺科杂志，2017，22（3）：513-516.
|
|
|
|
